tirzepatide and heart disease Cardiorenal benefits of tirzepatide. By reducing volume overload, Lower Risk of Cardiovascular Death

Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease

Circadian GLP-1 Secretion in mice is dependent on the intestinal microbiome for maintenance of diurnal metabolic homeostasis

In brief, adults with type 2 diabetes at high risk of a CV event were randomized to a GLP-1RA or placebo in addition to standard of care

the general population but there seemed to be a lot of confusion as to whether DPP-4 inhibitors can do the same thing

Per the SmPC and NICE guidance, treatment should be stopped after 12 weeks if the person has not lost at least 5% of their initial body weight

doi: 10.1146/annurev-phyto-020620-114550 81 ZechmannB